Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.
|Articles|September 1, 2010
Some things will never change for managed care
Whether you're moving forward with an acquisition, with a sale or by outsourcing, remember some things will never change.
Advertisement
In spite of all this dramatic transformation, I can think of many industry realities that aren't going to change. See if you agree:
In fact, MHE readers have a lot to say about managed care's near future. Watch for the complete State of the Industry 2011 forecast report next month. We'll bring you in-depth analysis on the emerging-and nagging-issues.
Advertisement
Related to this article
Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.
American Oncology Network’s Melody Chang, R.Ph., says 18% of its first 70 outpatient bispecific patients had CRS, all low grade with no hospitalizations.
A screening program in eight countries found early-stage type 1 diabetes in about 1 in 350 children with no family history of the disease.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.
Garza, an expert on hidradenitis suppurativa at Johns Hopkins, says increasing incidence of the disease on the Japanese island of Okinawa offer some "tantalizing clues" about reasons for the rising incidence.
Apothecary Pharma is recalling 22 vials of compounded tirzepatide and one NAD+ vial nationwide, citing a lack of assurance of sterility.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
More checks in the plus column for GLP-1s for obstructive sleep apnea | CHEST 2026
3
Algia Pharma completes investigational drug toxicology study for non-opioid acute pain regimen AlgiaPak
4
Rex Hoffman, M.D., on how a CMO balances competing priorities | HSES 2026
5